Recombinant nonimmunogenic staphylokinase
Phase 3Protein / enzyme
Recombinant nonimmunogenic staphylokinase is one of 39 small molecule programs targeting Ischemia. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
47 competitors in Ischemia
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Lovenox
SanofiApproved
Corlanor
AmgenApproved
Repatha
AmgenApproved
Taxol
TevaApproved
Remodulin
United TherapeuticsApproved
Bayer Aspirin
BayerApproved
Persantine
Boehringer IngelheimApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Caverject
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
COVID-191 trial
Pulmonary Embolism1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company
- SSupergene, LLC